8-K: Viatris Reports Q1 2025 Results, Reaffirms 2025 Outlook Despite Goodwill Impairment

Viatris Inc. reported its first quarter 2025 financial results, reaffirming its 2025 outlook while facing challenges including a significant goodwill impairment charge.

Summary

• Viatris Inc. reported first quarter 2025 financial results on May 8, 2025, and reaffirmed its 2025 outlook.
• Total revenues for Q1 2025 were $3.3 billion, an 11% decrease on a reported basis and a 2% decrease on a divestiture-adjusted operational basis compared to Q1 2024.
• Excluding the Indore Impact, total revenues would have increased 2% on a divestiture-adjusted operational basis compared to first quarter 2024.
• The company reported a U.S. GAAP net loss of $(3.0) billion, or $(2.55) per share, compared to a net income of $114 million, or $0.09 per share, in Q1 2024, primarily due to a $2.9 billion non-cash goodwill impairment charge.
• Adjusted EBITDA was $923 million, a 23% decrease on a reported basis and a 12% decrease on a divestiture-adjusted operational basis compared to Q1 2024.
• Adjusted EPS was $0.50 per share, a 25% decrease on a reported basis and a 14% decrease on a divestiture-adjusted operational basis compared to Q1 2024.
• U.S. GAAP net cash provided by operating activities was $535 million, and free cash flow was $493 million, including $43 million in transaction-related costs.
• The company returned more than $450 million of capital to shareholders year-to-date, including over $300 million in share repurchases and ~$143 million in dividends paid.
• Viatris is reaffirming its 2025 outlook, with U.S. GAAP net cash provided by operating activities estimated to be between $2.2 billion and $2.5 billion.
• The company expects $500 million to $650 million in total share repurchases in 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company reaffirms its outlook and highlights pipeline progress, the significant goodwill impairment charge and revenue decline weigh heavily on the overall assessment.

Positives

• Viatris reaffirmed its 2025 financial outlook.
• The company returned over $450 million to shareholders through share repurchases and dividends.
• Viatris made significant pipeline progress with positive Phase 3 data readouts for EFFEXOR, meloxicam (MR-107A-02), and XULANE LO.
• The company expects to generate $450 million to $550 million in new product revenues in 2025.
• The company plans to submit NDAs to the FDA for meloxicam (MR-107A-02) and XULANE LO.

Negatives

• Viatris reported a U.S. GAAP net loss of $(3.0) billion due to a $2.9 billion non-cash goodwill impairment charge.
• Total revenues decreased by 11% on a reported basis and 2% on a divestiture-adjusted operational basis.
• Adjusted EBITDA decreased by 23% on a reported basis and 12% on a divestiture-adjusted operational basis.
• Adjusted EPS decreased by 25% on a reported basis and 14% on a divestiture-adjusted operational basis.
• The company experienced a negative impact from the FDA warning letter and import alert related to its oral finished dose manufacturing facility in Indore, India (Indore Impact).

Risks

• The company faces potential continued or additional drug pricing reduction pressures.
• There is general uncertainty related to the timing of responses and approvals from the FDA.
• The company faces the potential for adverse impacts from future tariffs and trade restrictions.
• The company experienced a sharp and sustained decline in its share price and significantly increased uncertainty and volatility in the geopolitical and economic environments.
• The negative impact of the FDA issued warning letter and import alert related to our oral finished dose manufacturing facility in Indore, India.

Future Outlook

Viatris is reaffirming its 2025 outlook, expecting U.S. GAAP net cash from operating activities between $2.2 billion and $2.5 billion, and anticipates $500 million to $650 million in total share repurchases for the year. The company also expects to deliver approximately $450 million to $550 million in new product revenues in 2025.

Management Comments

• Scott A. Smith, CEO, stated that 2025 is off to a good start and expressed confidence in the company's ability to navigate industry volatility due to its growing pipeline, capital discipline, operational execution, and global scope.
• Doretta Mistras, CFO, highlighted the company's strong cash flow and commitment to returning capital to shareholders.

Industry Context

Viatris operates in a challenging environment with increasing pricing pressures, regulatory uncertainty, and geopolitical volatility. The company's focus on strategic priorities, pipeline development, and capital allocation is aimed at navigating these challenges and delivering value to shareholders. The goodwill impairment charge reflects the impact of these factors on the company's valuation.

Comparison to Industry Standards

• Comparing Viatris to Teva Pharmaceutical Industries Ltd. (TEVA) and Mylan (prior to its merger with Upjohn to form Viatris), Viatris's revenue decline of 11% is within the range of challenges faced by generic pharmaceutical companies due to pricing pressures and competition.
• Teva, for example, has also faced revenue declines and restructuring efforts in recent years.
• However, the $2.9 billion goodwill impairment charge is significant and indicates a more substantial reassessment of the company's future prospects compared to some of its peers.
• Companies like Novartis and Pfizer, which have a stronger focus on innovative drugs, have generally shown more stable revenue streams, but they also face different sets of challenges related to R&D and regulatory approvals.

Stakeholder Impact

• Shareholders are impacted by the net loss and the decline in adjusted EBITDA and EPS, but may be reassured by the reaffirmed outlook and capital return program.
• Employees may be affected by restructuring activities and changes in manufacturing facilities.
• Customers and patients may benefit from new product launches and the company's commitment to providing access to medicines.
• Suppliers and creditors may be impacted by changes in the company's financial performance and strategic priorities.

Next Steps

• Submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for meloxicam (MR-107A-02) by the end of 2025.
• Submit an NDA to the FDA for XULANE LO in the second half of 2025.
• Continue to pursue regional licensing and partnership opportunities.
• Execute share repurchases of $500 million to $650 million in 2025.

Key Dates

Keywords

Viatris, financial results, Q1 2025, outlook, goodwill impairment, revenues, EBITDA, EPS, share repurchases, dividends, pipeline, FDA, meloxicam, XULANE LO, EFFEXOR, Indore Impact